Cell based therapy in Parkinsonism

Johannes PJM de Munter1,2*, Chongsik Lee3 and Erik Ch Wolters1,4

Abstract

Parkinson’s disease (PD) is a synucleinopathy-induced chronic progressive neurodegenerative disorder, worldwide affecting about 5 million humans. As of yet, actual therapies are symptomatic, and neuroprotective strategies are an unmet need. Due to their capability to transdifferentiate, to immune modulate and to increase neuroplasticity by producing neurotrophic factors, adult stem cells (ASC) might fill this gap. Preclinical research in 6-hydroxydopamine (6-OHDA) and/or 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) lesioned animals established persistent improvements of motor behavior after ASC-treatment. Histological/histochemical measurements in these animals evidenced an intracerebral applied ASC-induced increase of Tyrosine Hydroxylase-positive (TH+) cells with increased striatal dopamine levels, suggesting cell rescue. Likewise, clinical experience with subventricular applied ASCs in PD patients, although limited, is encouraging, evidencing neurorescue especially during the early phase of the disease. In multiple system atrophy (MSA) or progressive supranuclear palsy (PSP) patients, though, only marginal reduced progression of natural progression could be established after subventricular or intravasal ASC implantations.

Keywords: Adult stem cells, Parkinson’s disease, Multiple system atrophy, BDNF, GDNF, Expanded MSC, Preclinical

Introduction

Parkinson’s disease (PD) is the most common chronic progressive neurodegenerative disorder after Alzheimer’s disease [1], world-wide affecting nearly 5 million people aged 50 years or more, and expected to double over the next 20 years [2]. It comes with a twofold higher mortality rate, mainly due to pneumonia, shortening life expectancy with nearly 10 years [3,4]. The result of the α-synucleinopathic degeneration of the nervous system, starting in the peripheral nervous system and lower brainstem and progressively extending over the upper brainstem and neocortex, symptomatology in PD comprises dysfunctions of the whole nervous system. It may start with a range of non-motor symptoms such as disorders of the autonomic nervous system, olfaction, sleep, mood and subtle cognitive deterioration, before a degeneration of the dopamine producing cells in the upper brainstem (nigral substance) may manifest with motor parkinsonism, the clinical hallmark of this disease, and way before involvement of the neocortex induces dementia [5]. PD is mainly recognized when first symptoms of motor parkinsonism (hypokinesia, bradykinesia, rigidity, tremor and the loss of postural reflexes) develop as the result of the loss of the majority of the dopaminergic neurons of the pars compacta of the substantia nigra with a striatal dopaminergic depletion of over 80% [6]. As of yet, treatment in PD is based on the pulsatile (oral) or continuous (subcutaneous, intrajejunal) suppletion of the striatal dopamine deficiency with dopamine agonists and/or the dopamine precursor levodopa, mostly in combination with a peripheral dopa decarboxylase inhibitor and/or in combination with inhibitors of mono-amine oxidase B (MAO-B) and/or catechol-O-methyl transferase (COMT), in order to restore striatal dopaminergic denervation [7].

Actual therapy only symptomatically affects motor parkinsonism, though. Therapies affecting non-motor symptomatology, and above all protective or restorative treatments are unmet needs in PD. In order to reach these needs, recently, experiments with cell based therapies to rescue or replace dopamine-secreting cells, or with cells able to secrete paracrine factors modulating brain tissue repair were initiated [8-12].

In this review, these experimental stem cell based therapeutic strategies will be discussed. As the application of embryonic stem cells and induced pluripotent stem cells comes with an unacceptable risk of tumor induction [13-16], this review will only cover experiments dealing with expanded, whether or not genetically

* Correspondence: h.demunter@hetnet.nl
1Department of Neurosciences University Maastricht, Maastricht, The Netherlands
2Amarna Stem Cells Group, Maastricht, The Netherlands
Full list of author information is available at the end of the article
modified, autologous or allogenic bone marrow-derived and/or neural progenitor stem cells.

**Adult stem cells (ASC)**

Adult stem cells comprise mesenchymal stem cells (MSCs), hematopoietic stem cells (HSCs) and ectodermal stem cells (ESCs). The majority of the cited preclinical and clinical studies use expanded and/or induced mesenchymal stem cells.

Re-implanted adult autologous stem cells, easily harvested out of the iliac crest and whether or not expanded, as a rule, will migrate towards diseased tissue, a phenomenon called homing [17,18]. Those stem cells have the potency to modulate immune responses [19,20] and to both transdifferentiate into target cells in order to replace damaged cells [21-24], and secrete paracrine (trophic) factors relevant for cell protection and cell repair by the inhibition of apoptotic pathways [25-27]. So, even before differentiation [28,29], mesenchymal stem cells, might express brain-derived neurotrophic factor (BDNF), glial cell-derived neurotrophic factor (GDNF) and stromal-derived factor (SDF-1α). BDNF is shown to have a neuroprotective effect on cultured rodent neurons via the P±kinase/Akt pathway by inhibiting neural death initiated by trophic factor withdrawal or by the exposure to nitric oxide [30]. GDNF provides neural protection against proteasome inhibitor-induced dopamine neuron degeneration [31], although its biological effect on the clearance of mature formed α-synuclein aggregation could not be observed, probably due to its short duration of administration [31]. SDF-1α, in low doses, promotes dopamine release from 6-OHDA-exposed PC12 cells (cell line derived from a pheochromocytoma), presumably by preservation and enhanced survival of these cells, as these phenomena are blocked by administration of anti-SDF-1α antibodies [32]. A high concentration of SDF-1α, however, rather enhances apoptosis [33]. SDF-1α acts through CXCR4 (chemokine receptor type 4) resulting in a down regulation of caspase-3 and an activation of the PI3/Akt pathway [34]. SDF-1α also enhances the survival of neural progenitor cells through the receptors CXCR7 and CXCR4 by regulation of the ERK1/2 (Mitogen-Activated Protein kinase 3) endocytic signaling pathway [35].

The route of administration (intravasal, intraparenchymal) during the re-implantation of the stem cells seems to have a major impact on the specific transdifferentiation and/or secretion patterns of them, as the actual environment influences the further developments of these cells. However, by inducing stem cells before re-implantation it is also possible to induce these developments already in vitro. Indeed, by exposing these cells to trophic factors, including epidermic growth factor (EGF) and basic fibroblast growth factor (bFGF) [36], by transducing them with a viral vector, and/or by binding them to pharmacologically active microcarriers, containing trophic factors such as NT-3 (Neurotrophin-3) [37], it is possible to further differentiate the stem cells, prior to the re-administration to the target organs [38,39]. So, in vitro, adult stem cells may be predisposed to differentiate into dopamine producing cells [21,40], thus offering a potential alternative for dopamine substitution therapies, or into cells secreting neuroprotective and/or neurorestorative trophic factors, thus protecting for dopaminergic cell death respectively stimulating neurorestoration [41].

Due to the lung trap [42] and the blood–brain-barrier [43,44], intravasal application of stem cells for disorders of the central nervous system is suggested less effective as compared to intracerebral administration [23,45].

**Preclinical experience with ASC in motor parkinsonism**

In experimental animals, motor parkinsonism (but not PD) might be induced by intranigral 6-hydroxydopamine (6-OHDA) as well as by subcutaneous carbobenzoxy-leuc-leuc-leucinal (MG-132) and/or subcutaneous or intravasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) [46,47]. MPTP models have the advantage that the lesions are induced through a less invasive (subcutaneous or intravasal) route of administration as compared with the stereotactic surgical approach when applying 6-OHDA. To optimally investigate neural protection, the non-human primate MPTP model seems to be preferred [46]. Tables 1 and 2 present the results of preclinical interventions using cell-based strategies in the 6-OHDA, MPTP and the proteasome inhibitor MG-132 animal models. In all the presented animal studies immune suppression was used to prevent rejection of the cells. However, the use of immune suppression may influence not only the behavior of the Stem Cells [48] but also the severity of the lesions in animal models [49,50].

As might be appreciated, in the studies reviewed in Tables 1 and 2, the following stem cells were used:

- Expanded bone marrow-derived mesenchymal cells (of the mesodermal lineage) of rat [32,37,51-53], mouse [54] or human origin [55-58];
- Expanded and enriched, or epigenetically induced bone marrow-derived mesenchymal stem cells [37,51,55,56], enabling functional development before actual transplantation;
- Expanded neural stem cells of the ectodermal lineage, derived from the subventricular zone of the rat [59] or from a cultured fetal human cell line [60,61].

But for three studies with intravenous [32,54] and/or intranasal [53] application, all stem cells are applied intranigral and/or intrastriatal.

Outcome measures comprised motor behavior (rotational behavior) as well as histological/histochemical measures. The main findings on the rotational motor
### Table 1 Placebo-controlled stem cell applications in rodent animal models of parkinsonism

| Authors animals (Sprague–Dawley rats) | Product expanded allogenic ASCs | Applic/Observ time | Characteristics/Dosages/Application | Outcome (* = p < 0.05/ ** = p < 0.01/ *** = p < 0.001) |
|---------------------------------------|---------------------------------|-------------------|-------------------------------------|--------------------------------------------------|
| Bouchez, Sensebe et al. [51]          | rMSCs                            | 14/35 days        | 1. No intervention (n = 6)          | Rotational behavior (turns/min)                    |
|                                       |                                 |                   | 2. Intrastriatal saline (n = 7)     | 1. No-intervention group: 23.8 ± 2.1              |
|                                       |                                 |                   | 3. Intrastriatal 1.8×10⁵ rMSCs (n = 7) | 2. Control saline-treated group: 25.1 ± 1.7       |
|                                       |                                 |                   |                                      |                                                  |
| Female rats                           | rMGSCs                           |                   | 4. Intrastriatal 1.8×10⁵ rMSCs (n = 7) | 3. MSC-treated group: 14.1 ± 3.3*                  |
|                                       |                                 |                   |                                      | 4. Enriched rMSC-treated group: 10.8 ± 1.7*        |
|                                       |                                 |                   |                                      | • TH-positive neurons:                             |
|                                       |                                 |                   |                                      | 1. No-intervention group: 24.2 ± 6.7%             |
|                                       |                                 |                   |                                      | 4. Enriched rMGSC-treated group: 52.5 ± 8.2%*     |
| Wang, Yasuhara et al. [32]            | Fibroblasts                      | 2 hr/28 days      | 1. Intravenous saline (n = 7)       | Amphetamine-induced rotational behavior            |
|                                       |                                 |                   | 2. Intravenous 10⁷ fibroblasts (n = 6) | 1. Control group: 8.5 ± 3.5 turns/min              |
| Female rats                           | rMSCs                            |                   | 3. Intravenous 10⁷ rMSCs (n = 6)    | 2. Fibroblast group: 8.2 ± 3.3 turns/min           |
|                                       |                                 |                   |                                      | 3. rMSC group: 1.2 ± 0.7 turns/min*                |
|                                       |                                 |                   |                                      | • Cylinder test                                    |
|                                       |                                 |                   |                                      | 1. Control group: 64.7 ± 17.3%                     |
|                                       |                                 |                   |                                      | 2. Fibroblast group: 60.2 ± 16.1%                 |
|                                       |                                 |                   |                                      | 3. rMSC group: 293 ± 13.7%*                        |
|                                       |                                 |                   |                                      | • Preservation of TH⁺ cells: 3* > 2 > 1            |
| Danielyan, Schafer et al. [53]        | rMSCs (EGFP labeled)             | 7,9/110–136 days  | Intrasinal saline day 7 and 9 (n = 7) | Stepping ratio (contralateral/ipsilateral) MSC-treated group 2 (0.7)** > group 1 (0.1) |
|                                       |                                 |                   | 1. Intrasinal 5x10⁵ MSC day 7 and 9 (n = 9) | Amphetamine-induced rotational behavior            |
|                                       |                                 |                   |                                      | MSC-treated group 4* < group 3                      |
|                                       |                                 |                   |                                      | • Histology                                        |
| Female rats                           |                                 |                   | 2. Intrasinal saline day 7 and 9 (n = 10) |                                                  |
|                                       |                                 |                   | Intrasinal 5×10⁵ MSC day 7 and 9 (n = 12) |                                                  |
| Blandini, Cova et al. [58]            | hMSCs                            | 5/28 days         | 1. Intrastriatal saline (n = 9)     | Apomorphine-induced rotational behavior            |
|                                       |                                 |                   | 2. Intrastriatal 1x10⁵ hMSCs (n = 8) | 1. No effect                                       |
| Male rats                             |                                 |                   |                                      |                                                  |
| Authors                        | Cells   | Days     | Lesion        | Results                                                                 |
|--------------------------------|---------|----------|---------------|-------------------------------------------------------------------------|
| Cova, Armentero et al. [57]    | hMSCs   | 5/28     | SHAM unilateral lesion | 1. Reduced rotational behavior*  
Expression of GDNF increased in hMSCs group  
Apoptosis decreased in hMSCs treated group  
Dose-dependent neurorescue effects (hMSCs vs saline) in unilateral 6-OHDA lesioned, but not SHAM lesioned, rats with |
| Male rats                      |         |          |               | 2. Reduced rotational behavior*   
Expression of GDNF increased in hMSCs group  
Apoptosis decreased in hMSCs treated group  
Dose-dependent neurorescue effects (hMSCs vs saline) in unilateral 6-OHDA lesioned, but not SHAM lesioned, rats with |
| Delcroix, Garbayo et al. [37]  | rMSCs   | 14/64    | 6-OHDA unilateral lesion | a) Reduction increased ongoing toxin-induced degeneration of dopaminergic terminals  
   b) Enhanced neurogenesis increased (neural progenitor cells) in the periventricular zone  
   c) Persistent release of specific cytokines |
| Female rats                    | rMSCs   |          |               | 1. Rotational behavior (turns/min):  
   1. saline treated group: 18.5  
2. rMSCs-treated group: 17.5  
3. rMSCs treated group: 8.5*  
4. rMSCs + P + NT3 treated group: 3.0* |
| Levy, Bahat-Stroomza et al. [56] | hMSCs   | 35/125   | 1. Intrastriatal saline in 5 | 1) Intrastriatal saline in 5 (n = 7)  
   Rotation behavior (turns/min) (post-lesional 100%) |
| Female rats                    | hiMSCs (neural phenotype) |          | 2) Intrastral 5x10^5 MSCs (n = 7) | 1) saline-treated group: 88% |
| Female rats                    | hiMSCs (BDNF/GDNF) |          | 2) Intrastral 1.5 or 4.5x10^5 hiMSCs (n = 21) | 1) saline group: increase 4.74 ± 1.07 turns/min  
   2. MSCs group: increase 2.86 ± 0.54 turns/min  
   3. hiMSCs group: increase 2.16 ± 0.37* turns/min  
   4. TH-positive area (treated versus untreated site) |
| Sadan, Bahat-Stromza et al. [55] | hMSCs   | 1 hr/42  | 1) Intrastriatal saline (n = 10) | 1) Intrastral 5x10^5 MSCs (n = 7)  
   Rotation behavior (turns/min) (post-lesional 100%)  
   Rotational behavior (turns/min) (post-lesional 100%) |
| Male rats                      | hiMSCs  |          | 2) Intrastral 1.5 or 4.5x10^5 hiMSCs (n = 21) | 1) intrastriatal saline in 5 (n = 7)  
   Rotation behavior (turns/min) (post-lesional 100%)  
   Rotational behavior (turns/min) (post-lesional 100%) |
| Zhu, Ma et al. [59]            | rNSCs   | 35/155   | 1. No intervention (n = 13) | 1) Group without intervention: 233.9 ± 70.43  
   2. rNSCs SNc group: 189.3 ± 63.24*** |
| Male rats                      |         |          |               | 2. Reduced rotational behavior*  
Expression of GDNF increased in hMSCs group  
Apoptosis decreased in hMSCs treated group  
Dose-dependent neurorescue effects (hMSCs vs saline) in unilateral 6-OHDA lesioned, but not SHAM lesioned, rats with |
behavior showed a significant reduction of turns/minute. But for 4/7 studies [32,51,53,58], in all studies with expanded MSCs [32,51,53,58], as well in all studies with expanded and enriched or epigenetically induced MSCs [37,51,55,56], and expanded neural stem cells [59,61], this reduction was established.

The administration of expanded, not-induced stem cells in these studies varied widely in relation to the onset of the toxin-induced motor parkinsonism. Stem cells were applied within 2 hours [32,55], within 5 to 14 days [57,58], or 30 days after the lesion [54,56,59-61]. Overlooking the effects in these studies on rotational behavior, the period in between application and lesioning seems to influence the clinical outcome: the earlier the application, the better the resulting clinical effects. Remarkably, after intravasal administration of ASCs, whether applied in the acute phase [32] or 3 weeks after lesioning [32], only a few ASCs (about 2%) could be detected in the nigral substance, the majority was trapped in the lungs. Nevertheless, also in these experiments, a significant beneficial effect on motor behavior could be established [32]. Here, it seems relevant to mention that after intrastriatal (intracaudate) application in the non-human primate MPTP model, 1% of the implanted stem cells could be identified at the injection site, whereas over 80% was found to be migrated to and along the impaired nigrostriatal pathways [60].

As for the histological/histochemical findings, after intracerebral stem cell application, in all experiments, more striatal TH-positive neurons were seen in the treated as compared to the non-treated, control lesioned animals, suggesting ASC-induced increased neuronal plasticity (neurorescue) with increased modulation of cell survival (and an increased striatal dopamine level), enhanced neurogenesis (progenitor cells in the subventricular zone), and a decreased modulation of inflammation, gliosis and death-signaling [51,52,55,57,59,62]. The same preservation of TH-positive cells was also observed after intravenous [32] and intranasal MSC application [53].

**Clinical experience with ASC in motor parkinsonism**

As of yet, only three studies were reported, dealing with the effects of, intracerebral or intravasal applied, allogenic or autologous adult stem cells in patients suffering motor parkinsonism in PD, multiple system atrophy (MSA) or progressive supranuclear palsy (PSP) [63-65]. The results are summarized in Table 3. In most but not all PD patients, the subventricular application of both, allogenic and autologous bone marrow-derived mesenchymal stem cells did improve clinical scores of motor behavior, as expressed in a significant decrease of

| Table 1 Placebo-controlled stem cell applications in rodent animal models of parkinsonism (Continued) |
|---------------------------------------------------------------|
| Ramos-Moreno, Castillo et al. [61] Female rats               |
| hNSCs                                                         |
| hiNSCs (expressing Bcl-X<sub>L</sub>)                         |
| 45/165 days                                                  |
| 1. Intrastratal saline (n = 15)                              |
| 2. Intrastratal 3x10<sup>5</sup> hNSCs (n = 17)               |
| 3. Intrastratal 3x10<sup>5</sup> hiNSCs Bcl-X<sub>L</sub> expression (n = 21) |
| 1. Control group: 18 turns/min                               |
| 2. hNSCs-treated group: 17 turns/min                         |
| 3. hiNSCs-treated group: 3 turns/min***                      |
| 1. Control group: 6.5 turns/min                              |
| 2. hNSCs-treated group: 2 turns/min**                        |
| 3. hiNSCs-treated group: 2.5/min**                          |

Abbreviations: 6-OHDA 6 hydroxydopamine, ASCs Adult stem cells, MSCs Mesenchymal stem cells, NSCs Neural stem cells, h human r rat, i induced or transduced, EGFP Enhanced Green Fluorescent Protein, BDNF Brain-Derived Neurotrophic Factor, GDNF Glial cell Derived Neurotrophic Factor, NT-3 Neurotrophine-3, P Pharmacologically active microcarriers, Bcl-X<sub>L</sub> anti-apoptotic granulocyte-colony stimulating factor enhancing the expression of key genes involved in dopaminergic patterning, differentiation and maturation; SNc Substantia Nigra pars compacta, TH<sup>+</sup> Tyrosine Hydroxylase Immunoreactive positive cells.
UPDRS scores in ON and OFF conditions. Interestingly, these effects did appear faster and more outspoken the earlier these interventions were applied, mimicking the results in preclinical experiments. Also Magnetic Resonance-tractography of degenerated dopaminergic projections did show significant improvements in those patients.

In MSA and PSP patients, compared to placebo-treated patients, in some patients, a temporary improvement or reduced deterioration in motor and cognitive functions [60] witnessed a reduction in natural progressive deterioration with subventricular or intravasal ASC implantations. This reduced disease progression in these patients was also found reflected in MRI (Magnetic Resonance Imaging)- and FDG PET (fluorodeoxyglucose positron emission tomography)-imaging, showing less atrophy and less decreased glucose metabolism in cortex and cerebellum.

**Discussion**

PD is a chronic progressive, diffuse α-synucleinopathic disease of the central nervous system in which (symptomatic) therapeutic strategies aim to compensate for the striatal dopamine deficiency in order to mainly decrease motor symptomatology. As of yet, protective/repairing therapeutic strategies in PD are an unmet need.

**Table 2** Placebo-controlled stem cell applications in animal models of parkinsonism

| Authors animals | Product expanded | Applic/Observ time | Characteristics/Dosages/Application | Outcome(* = p < 0.05 / ** = p < 0.01 / *** = p < 0.001) |
|-----------------|-----------------|--------------------|--------------------------------------|--------------------------------------------------|
| Male CS7BL/6 mice | mMSCs | Directly after last MPTP injection/1 month | 1. Intraperitoneal saline (n = 24) | • SN TH+ cells: 3** > 2 |
|                  |                  |                    | 2. Intraperitoneal MPTP + IV saline (n = 24) | • SN microglial cells: 3* < 2 |
| Park, Bang et al. [62] | hiMSCs | 1 day after last MPTP and 3-NP injection/28 days | 1. Intraperitoneal saline-treated (n = 10) | • Group 2 and 3: 48% loss of nigral cells; |
|                  |                  |                    | 2. Intraperitoneal MPTP + 3-NP (n = 8) | • Group 3 compared to group 2: |
|                  |                  |                    | 3. Intraperitoneal MPTP + 3-NP and IV 1×10^6 hiMSCs in 200 μl (n = 8) | a. 2% of hiMSCs in SN, and 4% in the Striatum |
| Bjugstad, Teng et al. [60] | hiNSCs | 4 and/or 6 months after last MPTP injection/4 (n = 3) and 7 months (n = 4) | Bilateral intrastriatal and unilateral intranigral implantation of each 10^6 hiNSCs (n = 7) in the intramuscular MPTP lesioned monkey | • >80% of hiNSCs immigrated along the impaired nigrostriatal pathway |
| African green Monkeys |                  |                    |   | • < 1% of a total of 2×10^6 hiNSCs implanted within the caudate nucleus (intrastrital) was identified at this site. |
| Park, Lee et al. [52] | hMSCs | 21 days/3, 4, 6, 7, 10 weeks | 1. MG-132 lesioned rats | • 1.7% hMSCs detected in the nigral substance |
|                  |                  |                    | 2. MG-132 lesioned rats treated during 3 weeks with weekly intravasal application of 10^6 hMSCs | • Survival of nigral and striatal TH+ cells* after hMSCs |
|                  |                  |                    | | • Increased striatal dopamine level* after hMSCs |

Abbreviations: ASCs Adult stem cells, IV Intravenous, MPTP 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, MSCs Mesenchymal stem cells, NSCs Neural stem cells, h human m mouse, i induced or transduced, MG-132 carbobenzoxy-Leu-Leu-leucinal, a proteasome inhibitor. SN Substantia Nigra, TH+ Tyrosine Hydroxylase Immunoreactive positive cells.
Generally speaking, stem cells, and specifically adult stem cells, pending their environment after re-implantation or pending their in-vitro induction, are supposed to not only differentiate into functional (neuronal) cells, including dopamine producing neurons, but to also easily expand and thus to deliver enough cells for transplantation.

Although differentiation and proliferation of bone marrow-derived stem cells are jeopardized by aging and chronic diseases including diabetes [66], renal failure [67] and ALS (Amyotrophic lateral sclerosis) [68], in PD patients, up to the 15th passage, ASCs are fully comparable to those of healthy age-matched individuals regarding phenotype,

### Table 3 Open label and placebo-controlled stem cell applications in clinical parkinsonism

| Authors                      | Patients | Product | Observ. time (months) | Characteristics/Dosages/Application                                                                 | Outcome (* = p < 0.05 / ** = p < 0.01) |
|------------------------------|----------|---------|-----------------------|-----------------------------------------------------------------------------------------------------|--------------------------------------|
| Venkataramana, Pal et al. [65]| Allogenic | 3, 6, 12 | 1. PD patients with bilateral subventricular intracerebral application of $2 \times 10^6$ /kg bodyweight MSCs in 2 ml (n = 8) | UPDRS in ON/OFF:                                                                      |
|                               |          |         |                       | a. In PD patients: permanently improved* compared with baseline during both ON (18%: 51.2 versus 62.3) and OFF (31.2%: 59.5 versus 86.5). Effect stronger in patients with disease duration < 5 years (ON 45.5%/OFF 56.7%) as compared to patients with a duration > 10 years (ON 6.3% OFF 12.4%). |
| PD patients                   | MSCs     |         | 2. MSA + PSP patients with bilateral subventricular intracerebral application of $2 \times 10^6$ /kg bodyweight MSCs in 2 ml (n = 4) |                                                        |
| MSA patients                  |          |         |                       | b. Some MSA/PSP patients temporarily improved. The effect was not correlated with disease severity and disease duration/MRI-tractography: |
| PSP patients                  |          |         |                       | a. PD patients, after implantation, did show a trend of steadily improvement in tractographical images in genu and peduncles. |
| Open Label                    |          |         |                       | b. MSA/PSP patients showed further reduction of tractographical images after stem cell implantation. |
| Venkataramana, Kumar et al. [64]| Autologous | 10-36   | PD patients (n = 7) with an UPDRS ON/OFF score 50.6/65.0 and a mean disease duration of 14.7 yr treated with $10^6$ MSCs/kg bodyweight in the subventricular zone | UPDRS in ON/OFF:                                                                      |
| PD patients                   | MSCs     |         |                       | a. In 3/7 patients there was a stable improvement of ON/OFF scores of 38% respect 22.9% with unchanged anti-parkinsonian medication. |
| Open Label                    |          |         |                       | b. In 3/7 patients after treatment, only marginal clinical effects were observed Anti-parkinsonian medication significantly reduced in 2 patients. |
| Lee, kim et al. [63]          | Autologous | 1, 2, 3, 4, 5, 6, 8, 10, 12 | Patients with Cognitive intact MSA-C (with UMSARS scores between 30 to 50) | UMSARS score                                                                      |
| MSA patients                  | MSCs     |         | 1. Placebo group: Intravenous or intra-arterial placebo (n = 17) | a. MSCs-treated patients showed a reduced* increase of UMSARS score compared to placebo treated patients. |
| Placebo controlled            |          |         | 2. MSCs group: $4 \times 10^6$ MSCs intravenously or intra-arterial (n = 14) | b. Intra-arterial application of MSCs was complicated with some MRI-detectable ischemic lesions Cognitive functions: Significantly* worsened in the placebo, but not in the MSCs-treated patients |
|                             |          |         |                       | MRI and FDG PET:  Shown significantly increased* gray cerebral cortical areas respectively more decreased cortical and cerebellar glucose metabolism in placebo-treated, as compared to MSCs-treated patients. |

Abbreviations: MSCs Mesenchymal stem cells, MSA multiple system atrophy, MSA-C multiple system atrophy, cerebellar type, PSP progressive supranuclear palsy, MRI magnetic resonance imaging, UMSARS unified MSA rating scale, FDG PET fluorodeoxyglucose positron emission tomography.
morphology and capacity to multi-differentiate [69], and are also able to inhibit T lymphocyte proliferation induced by mitogens.

Next to the multi-differentiated proliferative capacity, adult stem cells, and especially expanded and induced ASCs, may secrete an array of trophic factors. As a matter of fact they may specialize to express mainly such factors by induction in vitro through exposure to trophic factors (including epidermic growth factor EGF and basic fibroblast growth factor bFGF), by transduction with a viral vector and/or by binding these ASCs to pharmacologically active microcarriers, containing trophic factors such as NT-3 prior to the application. When adding epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF) to serum-free medium, in order to expand and induce human ASCs, the secretion of neurotrophic factors such as BDNF (normally neglectable) will increase to 125 ± 12 pg/day/10^6 ASCs [70]. Thus induced ASCs will function as a vehicle for adequate delivery of neurotrophic factors (BDNF and GDNF) when transplanted in the central nervous system [55,70].

It is suggested that ASC-produced neurotrophic factors such as GDNF and BDNF enhance neuroprotection with an increased modulation of cell survival and a decreased modulation of inflammation, gliosis and death signaling. These trophic factors thus stimulate neurorescue by better protection of α-synucleinopathic jeopardized neurons, including DA producing neurons. This effect was also reported in a MPTP animal model in which allogenic neural stem cells were applied unilateral [71]. The jeopardized DA producing neurons were rescued and this effect was also observed in the opposite side of the SN in which no stem cells were applied [71]. So, in PD patients, autologous ASCs, and especially expanded and/or induced ASCs, due to their capacity to increase neuroplasticity, theoretically not only offer an increased neuroprotection, but also an increased neuro-repair in PD patients resulting in a slowing down of natural progression in this debilitating disease.

In preclinical studies, the stimulated secretion of GDNF and BDNF by ASCs is found to result in a higher number of striatal TH-positive neurons in the rat lesioned striatum as compared to placebo-treated rats, accompanied with a higher striatal dopamine level and decreased rotational behavior [58,70]. Other ASC-produced trophic factors, such as basic fibroblast growth factor bFGF and epidermal growth factor EGF, seem to be more relevant for neurorestoration (synthesis of extracellular matrix). In rodents, the intranigral application of (adenovirus mediated) glial cell line derived neurotrophic factor (GDNF), one week before the ipsilateral nigral 6-OHDA lesioning, did rescue 70% of the nigral TH-positive cells as compared to 30% in the not-pretreated, lesioned (control) animals, resulting in a significantly reduced rotational behavior: 5.4 ± 15.2 turns/15-minutes versus 40.8 ± 25 turns/15-minutes (p < 0.05) [72]. Note however that each intracerebral needle-induced manipulation per se might initiate the secretion of the same neurotrophic factors and/or cytokines mimicking a clinical effect, which may confound the results of a placebo treatment [73,74].

In the preclinical studies, reviewed above, two studies were performed in which ASCs were locally applied within 2 hours after the application of a 6-OHDA unilateral lesion in rodents [32,55]. Both studies, reported a significant improvement in rotational behavior and in survival of TH positive neurons within 4–6 weeks. In the studies applying ASCs, and especially expanded non-induced ASCs, later on, in a more chronic phase of a lesion, no significant reduction in rotational behavior could be established [28]. In translation, the clinical effects of implantation of expanded MSCs in PD patients might profit their application in an early phase of their disease. Indeed, in PD patients, the clinical effects of stem cell application seem to relate with disease duration [60].

Finally, as ASCs are large cells, unable to cross the blood–brain barrier [44], intracerebral application seems to be superior to intravasal application, as only 1-2% of thus applied cells will reach the central nervous system [52]. Intranasal administration of MSCs, however, might offer an alternative, as this way of application in unilateral 6-OHDA-lesioned rodents did result in both, a significantly improved motor behavior and a significant decrease in inflammatory cytokines (suggesting a strong cell protective effect by inhibiting inflammation cascades) with 24% of the cells surviving for at least 4.5 month in the central nervous system [53].

Conclusions
In conclusion

- ASCs are capable of migrating to the lesioned cells/organs throughout the body, a phenomenon, which is called homing.
- ASCs are easily to harvest out of the iliac crest. Their number might be increased by expanding them, and their functions might be developed prior to re-application by inducing them. Unlike ASCs in patients with other chronic diseases, in PD patients those cells are not impaired.
- Expanded and/or induced ASCs may stabilize motor (and non-motor) parkinsonism in patients suffering PD and may be also Parkinson-plus syndromes, by increasing neural plasticity rather than by differentiating into neurons. Early in the disease, ASCs will promote neurorescue/neuroprotection by increasing immune modulation and reducing inflammation, especially when expanded.
(undifferentiated) ASCs are administered. Later in the disease, they mainly will promote neurorestoration, especially when induced (differentiated) ASCs are given.

- Neurotrophic factors such as BDNF and GDNF (mainly interfering with destructive pathways) play a major role in neuroprotection, whereas other growth factors such as EGF and bFGF (promoting synthesis of extracellular matrix) are more important in neurorepair. The best time to start with ASCs administration is in the very early phase of Parkinson's disease.

Competing interests
The authors declare that they have no competing interests.

Authors' contributions
JdM compiled the article and did the literature search and summarized the preclinical and clinical studies as a part of his PhD. JdM wrote the draft and invited the 2 co-authors to comment and revised the draft. EW is the promotor of JdM and reviewed the article critically and was also responsible for the completeness of the issues addressed in this article. CL as an experienced neurologist familiar with Parkinsonism revised the article to assure the translational aspects of the content and was especially responsible for revising the clinical part of the article. All authors read and approved the final manuscript.

Author details
1Department of Neurosciences University Maastricht, Maastricht, The Netherlands.
2Amarna StemCells Group, Maastricht, The Netherlands.
3Department of Neurology, Asian Medical Center University of Ulsan, Seoel, South Korea.
4Department of Neurology, UniversitaetsSpital, Zurich, Switzerland.

Received: 29 January 2013 Accepted: 2 June 2013
Published: 4 June 2013

References
1. Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J: Parkinson's disease, a 20-year follow-up study. [Epidemiol 2011, 3:119–128].
2. Marsden CD: Parkinsonism and related disorders. 3rd edition. VU University Press; 2010:143
3. Fox SH, Katzenschlager R, Lim SY, Ravina B, Seppi K, Coelho M, et al: Movement Disorder Society Evidence-Based Medicine Review Update: Third Editionth edition. VU University Press; 2010:399–411.
4. Hendte H, Graichen R, Colman A: Cell therapy and the safety of embryonic stem cell-derived grafts. Trends Biotechnol 2007, 25(12):5–22.
5. Lee AS, Tang C, Cao F, Xie K, van der Bogt K, Hwang A, et al: Effects of cell number on teratoma formation by human embryonic stem cells. Cell Cycle 2009, 8(16):2608–2612.
6. Ben-David U, Benvenisty N, Mayshar Y: Genetic instability in human induced pluripotent stem cells: classification of causes and possible safeguards. Cell Cycle 2010, 9(23):4603–4604.
7. Sadan O, Shemesh N, Cohen Y, Melamed E, Ofen D: Adult neurotrophic factor-secreting stem cells: a potential novel therapy for neurodegenerative diseases. Isr Med Assoc J 2005, 11(4):201–204.
8. Fillmore HL, Holloway KL, Gillies GT: Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005, 105(4):1815–1822.
9. Geeraerts T, Deiva K, M’Sika I, Salim H, Hery C, Tardieu M: Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005, 106(5):1755–1761.
10. Ben-David U, Benvenisty N, Mayshar Y: Genetic instability in human induced pluripotent stem cells: classification of causes and possible safeguards. Cell Cycle 2010, 9(23):4603–4604.
11. Sadan O, Shemesh N, Cohen Y, Melamed E, Ofen D: Adult neurotrophic factor-secreting stem cells: a potential novel therapy for neurodegenerative diseases. Isr Med Assoc J 2005, 11(4):201–204.
12. de Munter JP, Wolters EC: Autologous stem cells in neurology: is there a future? J Neural Transm 2013, 120(3–4):65–73.
13. Agarwal S, Pitterger MF: Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005, 105(4):1815–1822.
14. Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, Geroldi E, et al: Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005, 106(5):1755–1761.
15. Barzilai R, Kan L, Ben-Zur T, Buhlik S, Melamed E, Ofen D: Induction of human mesenchymal stem cells into dopamine-producing cells with different differentiation protocols. Stem Cells Dev 2008, 17(5):547–554.
16. Tropel P, Platet N, Platet JC, Noel D, Allorieux M, Benabdill AH, et al: Functional neuronal differentiation of bone marrow-derived mesenchymal stem cells. Stem Cells 2006, 24(12):2868–2876.
17. Ye Y, Zeng YM, Yan MR, Lu XF: Induction of human bone marrow mesenchymal stem cells differentiation into neural-like cells using cerebrospinal fluid. Cell Biochem Biophys 2011, 59(1):179–184.
18. Zeng R, Wang LW, Hu ZB, Guo WT, Wei IS, Lin H, et al: Differentiation of Human Bone Marrow Mesenchymal Stem Cells into Neuron-like Cells in Vitro. Spine 2011, 36(13):997–1005.
19. Gneccchi M, Zhang Z, Ni A, Dzuav VJ: Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res 2008, 103(11):1204–1219.
20. Xu YY, Chen L, Wang R, Hou WK, Lin P, Sun L, et al: Mesenchymal stem cell therapy for diabetes through paracrine mechanisms. Med Hypotheses 2007, 71(3):390–393.
21. Jager M, Hemigou P, Zilliken C, Herten M, Li X, Fischer J, et al: Cell therapy in bone healing disorders. Orthopedic reviews 2010, 2(2):79–87.
22. Croft AP, Przyborski SA: Mesenchymal stem cells expressing neural antigens instruct a neurogenic cell fate on neural stem cells. Exp Neurol 2009, 216(2):329–341.
23. Tondreau I, Lagneau L, Dejeneffe M, Massy M, Mortier C, Delforge A, et al: Bone marrow-derived mesenchymal stem cells already express specific neuronal proteins before any differentiation. Differentiation 2004, 72(7):319–326.
24. Wilkins A, Kemp K, Ginty M, Hares K, Mallam E, Scolding N: Human bone marrow-derived mesenchymal stem cells secrete brain-derived neurotrophic factor which promotes neuronal survival in vitro. Stem Cell Res 2009, 363–70.
25. Du Y, Li X, Yang D, Zhang X, Chen S, Huang K, et al: Multiple molecular pathways are involved in the neuroprotection of GDNF against proteasome inhibitor induced dopamine neuron degeneration in vivo. Exp Biol Med 2008, 233(7):881–890.
26. Wang F, Yasuhara T, Shingo T, Kameda M, Taji N, Yuan WJ, et al: Intravenous administration of mesenchymal stem cells exerts therapeutic effects on parkinsonian model of rats: focusing on neuroprotective effects of stromal cell-derived factor-1alpha. BMC Neurosci 2010, 11(52):1–9.
27. Gereerts T, Deiva K, M’Sika I, Salim H, Hemy C, Tardieu M: Effects of SDF-1alpha and gp120 on the development of SK-N-SH neuroblastoma cells. Neurosci Lett 2006, 399(1–2):115–120.
28. Shyu WC, Lin SZ, Yen PS, Su CY, Chen DC, Wang HU, et al: Stromal cell-derived factor-1alpha promotes neuroprotection, angiogenesis, and mobilization/homing of bone marrow-derived cells in stroke rats. J Pharmacol Exp Ther 2008, 324(2):834–849.
29. Zhu B, Xu D, Deng X, Chen Q, Huang Y, Peng H, et al: CXCL12 enhances human neural progenitor cell survival through a CXCR7- and CXCR4-mediated endocytic signaling pathway. Stem Cells 2012, 30(1):2571–2583.
36. Delcroix GJ, Curtis KM, Schiller PC, Montero-Menei CN: EGF and bFGF pre-treatment enhances neural survival and specification and the response to neuronal commitment of MIAMI cells. *Differentiation* 2010, 80(4–5):213–227.

37. Delcroix GJ, Garbayo E, Sridji L, Thomas O, Vapnouille-Box C, Schiller PC et al: The therapeutic potential of human multipotent mesenchymal stromal cells combined with pharmacologically active microcarriers transplanted in hemiparkinsonian rats. *Biotechnology* 2011, 22(9):1560–1572.

38. Blits B, Kluyt BM, Farahvar A, Caperton CV, Dietrich WD, Burge MB: Lentiviral vector-mediated transduction of neural progenitor cells before implantation into injured spinal cord and brain to detect their migration, deliver neurotrophic factors and repair tissue. *Restor Neurol Neurosci* 2005, 23(5–6):313–324.

39. Bjorklund A, Kirk D, Rosendal C, Georgievka B, Lundberg C, Mandel R: Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer to the nigrostriatal system in the rat Parkinson model. *Brain Res* 2000, 886(1):2–98.

40. Chen L, He DM, Zhang Y: The differentiation of human placenta-derived mesenchymal stem cells into dopaminergic cells in vitro. *Cell Mol Biol Lett* 2009, 14(3):528–536.

41. Kim YJ, Park HJ, Lee G, Bang OY, Ahn YH, Joe E et al: Neurorative effects of human mesenchymal stem cells on dopaminergic neurons through anti-inflammatory action. *Glia* 2009, 57(1):13–23.

42. Fischer UM, Harting MT, Jimenez F, Monzon-Posadas WX, Xue H, Savitz SJ et al: Pulmonary passage is a major obstacle for intracerebral stem cell delivery: the pulmonary first-pass effect. *Stem Cells Dev* 2009, 18(5):683–692.

43. Jackson JS, Goldberg JP, Chapon C, Jones WA, Bhakoo KR: Homing of stem cells to sites of inflammatory brain injury after intracerebral and intravenous administration: a longitudinal imaging study. *Stem Cells Transl Med* 2010, 1(2):11–21.

44. Stamatovic SM, Keep RF, Andjelkovic AV: Brain endothelial cell-cell junctions: how to "open" the blood brain barrier. *Curr Neuropharmacol* 2011, 9(4):179–192.

45. Zhang C, Zhou C, Teng JJ, Zhao BL, Song YQ: Multiple administrations of human marrow stromal cells through cerebrospinal fluid prolong survival in a transgenic mouse model of amyotrophic lateral sclerosis. *Cytotherapy* 2009, 11(3):299–306.

46. Duty S, Jenner P: Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. *Br J Pharmacol* 2011, 164(6):1357–1391.

47. Garea-Rodriguez E, Schluhombo C, Czeh B, Konig J, Helms G, Heckmann C et al: Visualizing dopamine transporter integrity with iodine-123-FP-CIT SPECT in combination with high resolution MRI in the brain of the common marmoset monkey. *Neurosci Methods* 2012, 210(2):195–201.

48. Guo J, Zeng Y, Liang Y, Wang L, Su H, Wu W: Cyclosporine affects the proliferation and differentiation of neural stem cells in culture. *Neuroreport* 2007, 18(9):863–868.

49. Ibarra A, Corea D, Wilkins K, Merchant MT, Guizar-Sahagun G, Griñalva JL et al: Effects of cyclosporin-A on immune response, tissue protection and motor function of rats subjected to spinal cord injury. *Brain Res* 2003, 979(1–2):165–178.

50. Palladini G, Canot B, Pozzessere G, Teichner A, Buttarelli FR, Morselli E et al: Treatment with cyclosporine A promotes axonal regeneration in rats submitted to transection of the spinal cord–II-Recovory of function. *J Hirnforsch* 1996, 37(1):145–153.

51. Bouchez G, Sensei L, Vouc P, Garreau L, Boccard S, Rico A et al: Partial recovery of dopaminergic pathway after graft of adult mesenchymal stem cells in a rat model of Parkinson's disease. *Neurochem Int* 2008, 52(7):1332–1342.

52. Park HJ, Lee PH, Bang OY, Ahn YH, Joo IS, Huh K: Autologous mesenchymal stem cell therapy delays the progression of neurological deficits in patients with multiple system atrophy. *Clin Pharmacol Ther* 2008, 83(5):723–730.

53. Venkataramana NK, Kumar SK, Babaraju S, Radhakrishnan NC, Bansal A, Diet B et al: Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson's disease: translational research - the journal of laboratory and clinical medicine 2010, 155(2):626–70.

54. Lee PH, Kim JW, Bang OY, Ahn YH, Joo IS, Huh K: Neuroprotective effect of human mesenchymal stem cells in an animal model of double toxin-induced multiple system atrophy parkinsonism. *Cell Transplant* 2011, 20(6):857–865.

55. Levy YS, Bahat-Stroozma M, Barzilay R, Burstein E, Bulvik S, Barhum Y et al: Protective effects of neurotrophic factor-secretting cells in a 6-OHDA rat model of Parkinson's disease. *Stem Cells Dev* 2009, 18(8):1179–1190.